ESIC CENTRAL RATE CONTRACT NO. -145

Transcription

1 ESIC CENTRAL RATE CONTRACT NO FOR SUPPLY OF DRUGS & DRESSINGS (VALID FROM 3rd MAY, 2018 to 2nd MAY, 2020) HORMONES DRUGS USED IN INFECTIONS AND INFESTATIONS ANAESTHETIC AND AGENTS FOR PRE-MEDICATION FLUIDS AND ELECTROLYTES STRICTLY FOR OFFICIAL USE =.J EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI

2 ESIC CENTRAL RATE CONTRACT NO FOR SUPPLY OF DRUGS & DRESSINGS {VALID FROM 3rct MAY, 2018 to 2"ct MAY, 2020) HORMONES DRUGS USED IN INFECTIONS AND INFESTATIONS ANAESTHETIC AND AGENTS FOR PRE-MEDICATION FLUIDS AND ELECTROLYTES STRICTLY FOR OFFICIAL USE PUBLISHED BY DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI

3 Sno. Contents Page No. 1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A). 2. List of Approved Pharmaceutical firms Address with Terms & Conditions of the 1-8 Eligible firms - 4. Index Rate Schedule 1-18

4 REGISTERED STRICTLY FOR OFFICIAL USE ONLY HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION PANCHDEEP BHA WAN: C.I.G. ROAD: NEW DELID TeiFax: , (An IS :2008 Certified) No.U-25/12/142/2017-Med. V/RC 145 Dated: 3ra May, 2018 From: To The Director General, E. S.l. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI The Director, ESI Scheme- All States Medical Superintendent- ESIC Model Hospitals Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 145 EFFECTIVE FROM TO Sir I Madam, Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, Further, the following instructions are issued to govern operation of the Rate Contract. 1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs. I

5 2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof. 3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account. 4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order. SUPPLIES 5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone. 6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills. 7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers. 8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The II

6 Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract. 9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract. 11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated}, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply. 12. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market. 13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit. 14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under. Ill

7 15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected. b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances. c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to IP I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract. g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia. h) Packing should be able to prevent damage or deterioration during transit. i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. j) It should be ensured that lsi Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lsi Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards. 16. life Period : a) For Drugs having shelf life of Two years or less: Drug supplied should not be older than one fourth (1/4) of its shelf life from the date of manufacture. b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture. c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply. 17. Pharmacopoeia Specifications: Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act. IV

8 18. Testing of Drugs- Quality Control a) Approved Rate Contract Holder should submit a Test Report that particular batch of medicines tested by the Government/ Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply. b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action. c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs. d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory. e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the v

9 particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed. f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier. The classification of defects into different categories is as per the guidelines issued by the Drug Controller of India & action will be taken by ESIC for each category of defects. described as under:: A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)- lf any item I Batch of the item declared Not of Standard quality {NSQ) under Category A. Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug. B. CATEGORY 'B' DEFECT {Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual! individuals arising due to consumption of item declared NSQ and in case of VI

10 any adverse reaction reported in the Hospital during administration of the drugs. II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category B within a year Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. VII

11 il. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. 19. DeliverY Period - Risk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer. c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the VIII

12 pharmaceutical firm, in full at discretion o'f Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years. d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate. 20. Payment a. Payment may be made directly to the firm. Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract. b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions. IX

13 c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding. d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever. e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm. f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit. 21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts. 22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: - i. The Contractor shall be liable to be debarred for supplying medicines I drugs etc. to the Corporation for a period not exceeding five years. ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:- PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O. No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if Drug Date penalty pending levied X

14 24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase. 25. No other document should be entertained for giving any cognizance for placing the supply orders. 26. Acceptance letter issued to the firms by this office cannot be used for placing orders. Receipt of this letter may please be acknowledged. Encl.: As above. Yours faithfully, Copy to: 1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract. 2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States). DY. MEDICAL C~;;;ONER (RC) XI

15 Approved Vendor list r-- SNO. FIRM NAME - 1 Abbott Healthcare Private Limited 2 Abbott India Limited 3 ALBERT DAVID LIMITED 4 ASTRAZENECA PHARMA INDIA LIMITED 5 Baxter (India) Pvt. Ltd. 6 BHARAT PARENTERAL$ LIMITED 7 Bharat Serums and Vaccines Limited 8 Boehringer lngelheim India Pvt. Ltd. 9 CADILA HEALTHCARE LTD 10 Cadila Pharmaceuticals Limited 11 Cipla Ltd 12 Dr Reddys Laboratories Limited 13 Eli Lilly and Company (India) Pvt. Ltd. 14 Fresenius Kabi India Pvt Ltd 15 GlaxoSmithKiine Pharmaceuticals Ltd 16 GLEN MARK PHARMACEUTICALS LIMITED 17 Hab Pharmaceuticals & Research Ltd 18 Johnson & Johnson Private Limited 19 Lupin Ltd. 20 Merck Specialities Pvt Ltd 21 MSD PHARMACEUTICALS PVT LTD 22 Novartis Healthcare Pvt Ltd 23 Novo Nordisk India Pvt. Ltd. 24 ORGANON INDIA PVT LTD 25 OVERSEAS HEALTH CARE PVTLTD 26 Sanofi India Limited 27 SERDIA PHARMACEUTICALS (INDIA) PVT. LTD. 28 THEM IS MEDICARE LIMITED 29 USV Private Limited 30 WALLACE PHARMACEUTICALS PVT LTD 31 Zuventus Healthcare Limited Page 1 of 1

16 Abbott Healthcare Private Limited Floor 17, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai Maharashtra Tel: , Term 4 institution.business@abbott.com & imran.dar@abbott.com Abbott India Limited Floor 16, Godrej BKC, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai Maharashtra Tel: , Term 4 institut:ion.business@abbott.com & imran.dar@abbott.com AlBERT DAVID LIMITED 4/11 ASAF All ROAD NEW DELHI Tel: , , ~ Term 4 dispatch) of supply order on FOR Destination ba~~ adl_institution@yahoo.com ASTRAZENECA PHARMA INDIA LIMITED BLOCK N112TH FLOOR MANYATA EMBASSY BUSINESS PARK RACHENAHALLI OUTER RING ROAD BANGALORE KARNATAKA Tel: , , Term 4 institution.az@astrazeneca.com Page 1 of8

17 Baxter (India) Pvt. Ltd. 2nd Floor, Tower C, Building 8, DLF Cyber City, DLF Phase II Gurgaon Haryana Tel: , Term4 BHARAT PARENTERALS LIMITED Survey No. 144 & 146, Viii. Haripura Tal. Savli, Dist. Vadodara, Gujarat State Gujarat Tel: Term 4 pankajshah@bplindia.in Bharat Serums and Vaccines limited 3rd Floor, Liberty Towers, Plot No. 10 Kalwa Industrial Estate, Airoli, Navi Mumbai Tel: , Term4 sunil.kanhere@bharatserums.com Boehringer lngelheim India Pvt. Ltd. 1102, 11th Floor, Hallmark Business Plaza, Near Guru Nanak Hospital Road, Sandra East, Mumbai Maharashtra Tel: /78, , Term4 sandeep.kaul@boehringer-ingelheim.com & anurag.sharma@boehringer-ingelheim.com Page 2 of8

18 CADILA HEALTHCARE LTD Zydus Tower, Sate lite Cross Roads Ahmedabad Gujarat Tel: , Term3 Term 4 sandeep.sarkar@zyduscadila.com Cadi Ia Pharmaceuticals Limited Cadila Corporate Campus, Sarkhej Dholka Road, Bhat, Ahmedabad , Gujarat Tel: Term 4 Delivery within 6{six) weeks (of the actual date of jaideep.nair@cadilapharma.co.in, uthaman.nair@cadilapharma.co.in & ashwini.prajapati@cadilapharma.co.in Cipla Ltd Cipla Limited, Mumbai Central, Mumbai Maharastra Tel: Term4 Delivery within 6{six) weeks (of the actual date of manojkumar.singh@cipla.com Dr Reddys Laboratories Limited , Ameerpet , Hyderabad Telangana Tel: Term4 Delivery within 6{six) weeks (of the actual date of jasveerm@drreddys.com & ibtpricing@drreddys.com Page 3 of8

19 Eli Lilly and Company (India) Pvt. Ltd. Plot No 92, Sector 32 Gurgaon (Haryana) Tel: , Term 4 sharma_vivek@lilly.com, singh_inderpal@lilly.com & tendersinfo@lilly.com Fresenius Kabi India Pvt Ltd Fifth Floor, A-wing, Ashoka Plaza, Survey No. 32/2, Pune-Nagar Road, Vadgaon Sheri, Pune , Mahasthra, India Tel: , , Term4 mohammad.alim@fresenius-kabi.com GlaxoSmithKiine Pharmaceuticals Ltd GSK House, Dr.Annie Besant Road, Worli Mumbai Maharashtra Tel: , , Term 4 sunil.m.tawde@gsk.com & pankaj.x.popli@gsk.com GLEN MARK PHARMACEUTICALS LIMITED GLEN MARK HOUSE, B D SA WANT MARG, Chakala, ANDHERJ (EAST) MUMBAI MAHARASHTRA Tel: /927, , Term4 shantaram.patil2@glenmarkpharma.com Page 4 of8

20 Hab Pharmaceuticals & Research Ltd 308,3rd Floor, T.V Industrial Estate S.K Ahire Marg behind Glaxo Lab, Worli Mumbai Maharashtra Tel: , , Term4 Johnson & Johnson Private Limited 8th Floor, ARENA SPACE OFF JVLR BEHIND MAJAS DEPOT, JOGESHWARI EAST MUMBAI MAHARASHTRA Tel: , , Term 4 sshind15@its.jnj.com lupin ltd. 3rd Floor, Kalpataru Inspire, Off W.E. Highway, Santacruz (East) Mumbai Maharashtra Tel: Term4 vijaymadan@lupin.com Merck Specialities Pvt Ltd Godrej One, 8th floor, Pirojshanagar, Eastern Express Highway, Vikroli East, Mumbai Mumbai Maharashtra Tel: , , Term 4 nitesh.sharma@merckgroup.com Page 5 of8

21 MSD PHARMACEUTICALS PVT LTD loth Floor, Platina Building, Next to City Bank, C-59, Block-G, Bandra Kurla Complex, Bandra (E) Mumbai Maharashtra Tel: Term 4 amit.kohli2@merck.com & contactmsdindia@merck.com Novartis liealthcare Pvt Ltd 201 Palika Bhawan Sector XIII R K Puram New Delhi Tel: , Term 4 rajender.arora@novartis.com & puru.gupta@novartis.com Novo Nordisk India Pvt. Ltd. Plot No. 32, EPIP Area, Whitefield, Bangalore Karnataka Tel: , , Term 4 surj@novonordisk.com ORGANON INDIA PVT LTD 10th Floor, Platina Building, Next to City Bank, C-59, Block-G, Bandra Kurla Complex, Bandra (E) Mumbai Maharashtra Tel: Term 4 amit.kohli2@merck.com & contactmsdindia@mercl<.com Page 6 of8

22 OVERSEAS HEALTH CARE PVT LTD 335 KM MILESTONE, NH N0.1, P.O.BOX-25 PHILLAUR PUNJAB Tel: , , Term4 Sanofi India limited Sanofi House, CT S No. 117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai Tel: , Term4 Delivery within 6{six) weeks (of the actual date of institution.business@sanofi.com SERDIA PHARMACEUTICALS (INDIA) PVT. LTD. Serdia House, Off. Dr. S. S. Rao Road, Pare! Mumbai Maharashtra Tel: / Term4 serdia.sales@in.netgrs.com THEMIS MEDICARE LIMITED 11/12, Udyog Nagar, SV Road, Gorefaon(West), Mumbai Tel: , Term4 Delivery within 6(six) weeks (ofthe actual date of instmgr@themismedicare.com & elizabeth@themismedicare.com Page 7 of8

23 USV Private Limited Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai Maharashtra Tel: Term 4. WALLACE PHARMACEUTICALS PVT LTD B FLORAL DECK, PLAZA. OFF CENTRAL MIDC ROAD, ANDHERI (EAST), MUMBAI MAHARASHTRA Tel: , , Term 4 ms379@hotmail.com & pravinwani@wallacepharma.net Zuventus Healthcare limited Office No 5119, 5th Floor, D wing, Oberoi Garden Estates, Chandivali, Andheri (East), Mumbai Maharashtra Tel: I , I 28, , Term4 sheetal.khanvilkar@zuventus.com Page 8 ofs

24 INDEX. (RC 145} -- - Sno. Item No. Item Name and Description Unit Page No b DYDROGESTRONE 10mg TAB 1 tab CABERGOLINE O.Smg TAB 1 tab 1 Recombinanant Follicle Stimulating Hormone or r-fsh (Follitrophine Beta) 100 IU/0.5 ml soln. for lnj. 1 vial Dapagliflozin 5mg Tab 1 tab a HUMAN CHORIONIC GONADOTROPIN 2000 IU INJ lmlamp c HUMAN CHORIONIC GONADOTROPHIN IU INJ 1mlamp 2 DEXAMETHASONE INJ- Each ml to contain: Dexamethasone Sodium Phosphate 4 mg. 1 vial b TRIAMCINOLONE INJ- Each ml: Triamcinolone 40mg 1m I vial SITAGLIPTIN 100mg TAB ltab 2 GLICLAZIDE & METFORMIN ER TAB- Each uncoated bi-layered scored tab to contain: Gliclazide IP (ER) 60 mg;metformin Hydrochloride IP (ER) SOOmg. ltab 3 THYROXINE SODIUM TAB- Each tab to contain: Thyroxine sodium IP 50mcg. 1 tab 3 THYROXINE SODIUM TAB- Each tab to contain:thyroxine sodium mcg 1 tab GLICLAZIDE TAB- Each tab to contain: Gliclazide 80mg. 1 tab 3 SITAGLIPTINE SOMG + METFORMIN 500MG TAB- Each Tab To contain: Sitagliptin 50mg, Metformin 500 mg. 1 tab 4 VILDAGLJPTIN 50 MG + METFORMIN HCL 500 MG TAB- Each Tab To contain: Vildagliptin 50 mg, Metformin Hydrochloride 500 mg. 1 tab SAROGLITAZAR 4mg Tab ltab Canagliflozin hemyhydrate equivaltent to Canagliflozin 100mg Tab 1 tab 4 Metformin Hydrochloride IP 500 mg (as a Sustained Release, Glimepiride IP 2 mg Tab 1 tab 5 Metformin Hydrochloride IP 500 mg (as a Sustained Release) Glimepiride IP 1 mg Tab ltab Empagliflozin 10mg Tab 1 tab 6 INSULIN ASP ART INJ- Each vial to contain: Insulin Aspart (R-ONA origin) 10m I 6 BIPHASIC INSULIIN ASP ART INJ- Each penfill to contain: Biphasic Insulin Aspart (R-ONA origin) 3m I penfill 6 INSULIN DETEMIR INJ- Each inj to contain: Insulin Detemir IU/ml (R-ONA) 3m I 6 INSULIN INJ- Each Cartridge to contain: 25% Lispro and 75% Lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, recombinant DNA origin] Cartridge 7 3m I Page 1 of 3

25 INDEX (RC 145} Sno. Item No. Item Name and Description Unit Page No. -- INSULIN INJ - Each Cartridge to contain: 50% Lispro and 50% lispro Protamine Suspension (100 IU/ml) [Monocomponent Insulin, recombinant DNA origin] Cartridge 7 INSULIN DEGLUDEC INJ- Each 1m I of the solution for subcutaneous inj to contain: Insulin Degludec (R-DNA origin) 100 unit/ml Pre Filled Pen 3ml PFP CLARITHROMYCIN 500mg TAB 1 tab 8 CEFUROXIME + CLAVULANATE POTASSIUM TAB- Each Tab b :Cefuro~me axetil 250mg, Clavulanate potassium 62.50Mg 1 Tab RIFAXIMIN 200mg TAB 1 Tab 8 Tab Clarithomycin 250mg+ Tab Tinidazole 500mg+ Cap Lansoprazole 30mg (one kit) lkit AZITHROMYCIN SYP- Each Sml : Azithromycin 100mg 15ml bot b TEICOPLANIN INJ- Each vial. to contain :Teicoplanin400mg. 1 vial VANCOMYCIN 500mg INJ 1 vial COLISTIMETHATE _SODIUM 10,00,000 I.U. INJ 1 vial 10 CEFTRIAXONE+TAZOBACTAM INJ- Each vial to contain: Ceftriaxone a 250mg, Tazobactam Sodium 31.25mg 1 vial LINEZOLID 600mg INJ, 1 vial ITRACONAZOLE 100mg TAB 1 Tab 10 3m I CASPOFUNGIN ACETATE 50mg INJ 1 vial JIRBINAFINE HYDROCHLORIDE 250mg TAB ltab FLUCONAZOLE 200MG IV INJ 100ml Bot. 11 UPOSOMAL LYOPHILIZED a "B INJ- Each vial to contain: Liposomal Amphotericin -B P SOmg (Lyophilized) 1 vial b ACYCLOVIR 400mg TAB 1 Tab 12 HUMAN INTERFERON BETA 1A INJ- Each PFS/vial to contain: Recombinant Human Interferon Betala 44mcg 1 PFS/vial b ETHAMBUTOL 400mg TAB 1 Tab a PYRAZINAMIDE 500mg TAB 1 Tab b PYRAZINAMIDE 750mg TAB 1 Tab ETHIONAMIDE 250mg TAB 1 Tab ISOFLURANE- Each 100m I to contain: lsoflurane 100ml b SEVOFLURANE INJ- Each 250ml to contain: Sevoflurane 250m I a SUCCINYLCHOLINE 50mg INJ 2mlamp c I<ETAMINE SOmg INJ 10m I vial ROCURONIUM 10mg INJ Sml. Vial 16 TRIPLE CHAMBER BAG- Each to contain: Triple Chamber Bag with Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose and Electrolytes separated by peel seals for Peripheral intravenous 1000ml 16 Page 2 of 3

26 INDEX (RC 145) Sno. Item No. Item Name and Description Unit Page No. TRIPLE CHAMBER BAG- Each to contain: Triple Chamber Bag with Lipid Emulsion (80% Olive Oil & 20% Soya Oil), Amino Acids, Glucose and Electrolytes separated by peel seals for Central Intravenous. 2000ml 16 SODIUM CHLORIDE & DEXTROSE INJ(FOR I.V.INFUSION) Containing: Dextrose anhydrous 5%w/v, Sodium chloride 0.9%w/v SOOml. 17 DEXTROSE INJ(FOR I.V INFUSION)- Containing: Dextrose Anhydrous a 5%w/v 500ml 17 DEXTROSE INJ(FOR I.V INFUSION)- Containing: Dextrose Anhydrous b 10%w/v SOOml 17 SODIUM CHLORIDE INJ (FOR IV INFUSION)- Containing: Sodium chloride 0.9% w/v SOOml. 17 MAINTENANCE SOLUTION FOR PAEDIATRIC USE- Each 100 ml to contain (in mmol/ L) Sodium 23.0, Chloride 20.0, Potassium 20.0, 500ml Acetate 23.0, Magnesium 1.50, Phosphate1.50. Bot. 17 POLYMER OF DEGRADED GELATIN (FOR IV INFUSION)- Each to contain: Polymer of Degraded gelatin 3.5 gm. Electrolytes & Distilled water to 100 mi. per 100 mi. SOOml bot 18 Page 3 of 3

27 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 I Item No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1148b DYDROGESTRONE TAB - Each tab to contain : Dydrogestrone 1 tab I.P./U.S.P.lO mg. Abbott India Limited 29.5/1 tab 10 tab FIRST DUPHASTON Rupees twenty nine paisa fifty only I 568 I CABERGOLINE TAB- Each tab to contain:cabergoline O.Smg. Hab Pharmaceuticals 36/1 tab 4 tab FIRST & Research ltd I 1 tab CABERDOST 0.5 Rupees thirty six only 2088 Each vial to contains: Recornbinanant Follicle Stimulating Hormone or r-fsh (Follitrophine Beta) 100 IU/0.5 ml soln. for lnj. ORGANON INDIA PVT LTD /1 vial 1 vial FIRST 1 vial RECAGON Mfg: N.V. Organon, The Netherlands Rupees two thousand three hundred eighty six paisa eighty one only I 2089 I Dapagliflozin: Each Tab. to contains Dapagliflozin Smg I 1 tab ASTRAZENECA 27/1 tab 28 tab (2x14) FIRST FORXIGA5MG PHARMA INDIA LIMITED Rupees twenty seven only 1157a HUMAN CHORIONIC GONAD. OTROP.IN IN.J- Each ml to contain: 1mlamp I Human Chorionic Gonadotropin 2000 IU Bharat Serums and /1ml Vial FIRST Hucog 2000 hp liq Vaccines limited amp Rupees one hundred fifty two paisa twenty five only Page 1 of 18

28 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/1.42/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 [ttem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1157c HUMAN CHORIONIC GONADOTROPHIN INJ - Each ml to lml amp contain: Human Chorionic Gonadotrophin IU Bharat Serums and 399/lml amp Vial FIRST Hucog 1000 hp llq Vaccines Limited 1 Rupees three hundred ninety nine only DEXAMETHASONE INJ - Each ml to contain: Dexamethasone Sodium Phosphate 4 mg. CADI LA PHARMACEUTICALS LTD 5/1 vial 2ml Vial FIRST 1 vial Dexasone Rupees five only l1590b I TRIAMCINOLONE INJ- Each ml to contain: Triamcinolone 40mg llmlvial CADI LA PHARMACEUTICALS LTD 21/lml vial lml Vial FIRST NA Rupees twenty one only I SITAGLIPTIN TAB- Each tab to contain: Sitagliptln loorrtg 11 tab MSD PHARMACEUTICALS PVT LTD /1 tab 7 tab FIRST JANUVIA loomg Mfg: Merck Sharp and Doh me Ltd., England Rupees thirty paisa seven nine one four only Page 2 of18

29 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3' to Saturday May 2"d 2020 [Item No [ Drug Description [Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1897 GLICLAZIDE & METFORMIN ER TAB- Each uncoated bi-layered scored tab to contain: Gliclazide IP (ER) 60 mg;metformin Hydrochloride IP (ER) SOOmg. SERDIA PHARMACEUTICALS (INDIA) PVT. LTD /1 tab 14tab FIRST 1 tab DIAMICRON XR MEX 500 Rupees ten paisa three five seven one only 343 THYROXINE SODIUM TAB - Each tab to contain: Thyroxine 1 tab sodium IP SOmcg. GlaxoSmithKiine 0.35/1 tab 100tab FIRST ELTROXIN 50 MCG Pharmaceuticals ltd I Rupees zero paisa thirty five only 1688 THYROXINE SODIUM TAB - Each tab to contain:thyroxlne 1 tab sodium 25mcg GlaxoSmithKiine 0. 75/1 tab 60tab FIRST Pharmaceuticals ltd Rupees zero paisa seventy five only ElTROXIN 25 MCG [1174 I GLICLAZIDE TAB- Each tab to contain: Gliclazide 80mg. Dr Reddys Laboratories Limited /1 tab 15 tab FIRST [1 tab Reel ide Rupees one paisa nine seven zero seven only SERDIA PHARMACEUTICALS (INDIA} PVT. LTD 4.286/1 tab 10tab SECOND DIAMICRON Rupees four paisa two eight six only Page 3 of18

30 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U -25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1766 SITAGLIPTINE SOMG + METFORMIN SOOMG TAB- Each Tab To 1 tab contain: Sitagliptin 50mg, Metformin 500 mg. MSD /1 tab 14 tab FIRST PHARMACEUTICALS PVTLTD Rupees fifteen paisa seven eight six four only JANUMET 50MG/500MG Mfg: Merck Sharp and Oohme B.V., The Netherlands 1768 VILDAGLIPTIN 50 MG + METFORMIN HCL 500 MG TAB - Each Tab To contain: Vildagliptin 50 mg, Metformin Hydrochloride 500 mg. Novart1s Healthcare Pvt Ltd 16.78/1 tab 10tab FIRST 1 tab Galvus Met 50mg/SOOmg Mfg: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore Rupees sixteen paisa seven thousand eight hundred only 2090 SAROGLITAZAR tab: Each uncoated tab to contains: 1 tab Saroglitazar 4 mg CADI LA HEALTHCARE 19.05/1 tab 10Tabs FIRST LIPAGLYN LTD Rupees nineteen paisa five only 2091 Each film coated tab to contains Canagliflozin hemyhydrate 1 tab equivaltent to Canagliflozin 100mg JOHNSON & 35.19/1 tab Box of 3x10 tab FIRST JNVOKANA 100MG JOHNSON PVT LTD Mfg: Janssen Cilag SpA, Rupees thirty five paisa nineteen only Italy Page 4 of18

31 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 [ttemno [ Drug Description [Packing irmname Firm Rate/ unit Firm Packing Preference Description of stores accepted 2092 Each uncoated tablet contains: Metformin Hydrochloride IP 1 tab 500 mg (as a Sustained Release, Glimepiride IP 2 mg USV PRIVATE 0.941/1 tab 15 tab FIRST Glycomet GP 2mg LIMITED J Rupees zero paisa nine four one only WALLACE PHARMACEUTICALS PVT LTD 1.38/1 tab 15 tab SECOND Walaphage-G-2 Cipla ltd Rupees one paisa thirty eight only 1.5/1 tab 15 tab THIRD Rupees one paisa fifty only EXERMET GM Each uncoated tablet contains: Metformin Hydrochloride IP I 500 mg (as a Sustained Release) Glimepiride IP 1 mg USV PRIVATE 0.862/ltab 15 tab FIRsl LIMITED ltab Glycomet GP lmg Rupees zero paisa eight six two only WALLACE PHARMACEUTICALS PVT LTD 0.955/1 tab 15tab SECOND Walaphage-G-1 Rupees zeto paisa nine five five only Cipla Ltd /1 tab 15 tab THIRD EXERMET GM 501 Rupees one paisa three nine three three only Page 5 of 18

32 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-2S/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 2094 Empagliflozin Tab: Each Empagliflozin 10 mg Boehringer lngelheim 31.75/1 tab India Pvt.Ltd. film coated tab to contains: 10tab FIRST ltab Jardlance 10 mg Mfg: Boehringer lngelheim Pharma GmbH & Co. KG., Germany Rupees thirty one paisa seventy five only 1487 INSULIN ASPART INJ - Each vial to contain: Insulin Aspart (R ONA origin) Novo Nordisk India 1400/10ml 10 ml Vial FIRST Pvt. Ltd. 10m\ NovoRapid 100 IU Mfg: Novo Nordisk A/S Novo Aile, Denmark Rupees one thousand four hundred only 1488 BIPHASIC INSUUIN ASPART INJ - Each penfill to contain: 3ml penfill Biphasic Insulin Aspart (R-DNA origin) Novo Nordisk India /3ml 5x3rnl Penfill FIRST NovoMix 30 Penfill Pvt. ltd. penfill Mfg: Novo Nordisk Producao Farmaceutica do Brazil Ltda., Brazil Rupees three hundred seventy eight paisa ninety five only 1593 INSULIN DETEMIR INJ- Each inj to contain: Insulin Detemir 100 IU/ml (R-DNA) Novo Nordisk India 708.5/3ml 5x3ml Prefilled FIRST Pvt. Ltd. Pen 3m I Levemir Flexpen Mfg: Novo Nordisk A/S Novo Aile, Denmark Rupees seven hundred eight paisa fifty only Page 6 of 18

33 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-2S/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description Firm Name Firm Rate/ unit Firm Packing Preference I Packing Description of stores accepted J 1691 INSULIN INJ - Each Cartridge to contain: 25% Lispro and 75% Lispro Protamine Suspension (100 IU/mL) [Monocomponent Insulin, recombinant DNA origin] ELl LILLY AND COMPANY (INDIA) PVTLTD 355.4/3ml cartridge 3ml Cartridge FIRST 3m I Cartridge Humalog M1x 25 Mfg: Eli Lilly ltalia S.P.A., Italy Rupees three hundred fifty five paisa forty only 1692 INSULIN INJ - Each Cartridge to contain: SO% Lispro and SO% Lispro Protamine Suspension (100 IU/mL) [Monocomponent Insulin, recombinant DNA origin] Ell LILLY AND COMPANY (INDIA) PVT LTD 355.4/3ml Cartridge 3ml Cartridge FIRST 3m I Cartridge Humalog Mix 50 Mfg: Lilly France S.A.S., France Rupees three hundred fifty five paisa forty only 1898 INSULIN DEGLUDEC INJ - Each lml of the solution for subcutaneous inj to contain: Insulin Degludec (R-DNA origin) 100 unit/ml Pre Filled Pen Novo Nordisk India 1440/3ml PFP 3 m I Prefilled FIRST Pvt. Ltd. Pen 3ml PFP Tresiba Mfg: Novo Nordisk A/S Novo Aile, Denmark Rupees one thousand four hundred forty only Page 7 of 18

34 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1693 CLARITHROMYCIN TAB - Each tab to contain: Clarithromycin 11 tab SOOmg Hab Pharmaceuticals 8.2/1 tab 10 x 10 tab FIRST CLARTICIN -500 & Research Ltd I Rupees eight paisa twenty only GLEN MARK PHARMACEUTICALS LIMITED 9.7/1 tab 10 tab SECOND MACLAR 500 Rupees nine paisa seventy only 1552b CEFUROXIME + CLAVULANATE POTASSIUM TAB - Each Tab to contain:cefuroxime axe til 250mg, Clavulanate potassium 62.50Mg BHARAT PARENTERALS LIMITED 8.55/1 Tab 10tab FIRST Rupees eight paisa fifty five only 1 Tab I RIFAXIMIN TAB- Each tab to contain: Rifaximin 200mg 11 Tab Lupin Ltd /1 Tab 10 'Tab FIRST Rcifax Rupees five paisa six two seven nine only 2095 Cipla Ltd Each kit to contains: Tab Clarithomycin 250mg+ Tab Tinidazole SOOmg+ Cap Lansoprazole 30mg 1 kit 59/1 kit 1 KIT (2 cap FIRST PYLOKIT each) Rupees fifty nine only Page 8 of 18

35 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May z"d 2020 ]Item No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1379 AZITHROMYCIN SYP - Each Sml to contain: Azithromycin 15m I bot 100mg OVERSEAS HEALTH 7.74/15ml bot 15 ML FIRST AZYSAFE LIQ 100MG CARE PVTLTD Rupees seven paisa seventy four only Cipla Ltd 21/15ml bot 15ML bott SECOND AZEE 100 DRY SYRUP Rupees twenty one only Ll 4~1~3~b ~j_t~e~ic~o~p~l~a~n~in~i~n~j--e~a~c~h~v~ia~l.~to~co~n~ta~i~n~:t~e~lc~olpl~a~ni~n~40~0~m~g. LI ~l~v~ia_l ~ Cipla Ltd 499/1 vial 400MG vial FIRST TICOCIN 400 Rupees four hundred ninety nine only Sanofi India Limited /1 vial 400mgvial SECOND Targocid lnj. 400 mg Mfg: SANOFI S.P.A., Italy Rupees one thousand eighteen paisa sixty six only 332 BHARAT PARENTERALS LIMITED VANCOMYCIN INJ- Each vial to contain: Vancomycin Hcl. Eqv. to Vancomycin SOOrng. 39.6/1 vial 1 vial FIRST 1 vial Rupees thirty nine paisa sixty only Cipla Ltd 78/1 vial SOOMG SECOND VANLID 500 Rupees seventy eight only Page 9 of 18

36 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2nd 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1694 COLISTIMETHATE SODIUM INJ - Each vial to contain: 1 vial Colistimethate Sodium BP 10,00,000 I.U. Cipla Ltd 144.5/1 vial 10ML FIRST XVLISTIN 1MIU Rupees one hundred forty four paisa fifty only GLENMARK 297/1 vial 1 vial SECOND COLYMONAS 1 MIU PHARMACEUTICALS LIMITED Rupees two hundred ninety seven only a CEFTRIAXONE+ TAZOBACTAM INJ - Each vial to contain: Ceftriaxone 250mg, Tazobactam Sodium 31.25mg Zuventus Healthcare 35/1 vial Vial FIRST Limited Rupees thirty five only 1 vial AUGTAZ 250 MG I I LINEZOLID INJ- Each vial to contain: Linezolid 600mg, GLEN MARK PHARMACEUTICAlS LIMITED 137/1 vial 300ML vial FIRST Rupees one hundred thirty seven only llvial LIZOLID IV 300ML IITRACONAZOLE TAB- Each tab to contain: ltraconazole loomg j1 Tab/capk GLEN MARK PHARMACEUTICALS LIMITED 7.7/1 Tab lotab FIRST CANDITRALlOOMG Rupees seven paisa seventy only JOHNSON & JOHNSON PVT LTD 52.23/1 cap 4cap SECONO SPORANOX loomg Rupees fifty two paisa twenty three only Page 10 of 18

37 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2 11 d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1697 CASPOFUNGIN ACETATE INJ- Each vial to contain: Caspofungin 1 vial Acetate SOmg MSD /1 vial 1 VIAL FIRST CANCIDAS 50MG PHARMACEUTICALS PVT LTD Rupees nine thousand three hundred seventy three paisa eighty one only Mfg: Merck Sharp and Oohme B.V., The Netherlands 1698 TERBINAFINE HYDROCHLORIDE TAB Each tab to 1 tab contain:terbinafine hydrochloride 250mg Cipla Ltd 3. 7/ltab 7 tab FIRST TERBICIP Rupees three paisa seventy only Hab Pharmaceuticals & Research Ltd 4.1/1 tab 10x7tab SECOND LAMIFil-250 Rupees four paisa ten only CADI LA PHARMACEUTICALS LTD 4.29/1 tab 7tab Tf.IIRD Rupees f()ur paisa twenty nine only NA 2035 FLUCONAZOLE 200MG IV INJ - Each 100m! to contain Fluconazole 200mg IV Fresenius Kabi India 28/lOOml Bot. 100 ml bott FIRST Pvt Ltd 100m! Bot. Fresocan 100 ml Rupees twenty eight only Page 11 of18

38 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 145 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 jjtemno I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1908 Cipla Ltd LIPOSOMAL lyophilized il "B INJ - Each vial to contain liposomal Amphotericin -B P SOmg (Lyophilized) 1527/1 vial 50MG FIRST 1 vial PHOSOME 50 I Rupees one thousand five hundred twenty seven Only j335b I ACYCLOVIR TAB- Each tab to contain: Acyclovir 400mg. Cipla Ltd 3.6/1 Tab 5 tab FIRST j1 Tab ACIVIR 400 DT Hab Pharmaceuticals & Research Ltd 3.85/1 Tab Rupees three paisa sixty only 10 x lotab SECOND CYCLORAX-400 Rupees three paisa eighty five only 1649 HUMAN INTERFERO. N BElA la INJ - Each PFS/vial to contain: 1 PFS/vial I Recombinant Human Interferon Betala 44mcg MERCK SPECIALITIES 33S0/1 PFS/ vial PFS FIRST Rebif 44mcg/0.5ml Mfg: PVTLTD Merck Serono S.p.A., Italy Rupees three thousand three hundred fifty only l Page 12 of 18